Fundraising FoxPfizer Ventures — Full Portfolio
35 tracked investments · listed companies and verified rows first
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPappas CapitalPfizer Venture Investments+7 more
A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.
BiotechMedia & EntertainmentAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)inPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Co-investorsNew Enterprise Associates (NEA)Pfizer Venture InvestmentsCorrelation VenturesOrbiMedOsage University PartnersOUP (Osage University Partners)+1 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersAdvent Life SciencesHBM Healthcare InvestmentsHBM PartnersNextech InvestOUP (Osage University Partners)+3 more
Bio Protocol is a decentralized science (DeSci) platform where people can fund, develop and govern tokenized early-stage scientific research from universities, companies and researchers.
AI & Machine LearningBiotechCrypto & Web3
Co-investorsBinance LabsBig Brain HoldingsPolymorphic CapitalSerafundSignature VenturesSMAPE Capital+3 more
BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)
Co-investors5AM VenturesPfizer Venture Investments
Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.
BiotechDeep TechMedical Devices
George Kassiotis(Co-founder)Drew Pardoll(Co-founder)Houman Ashrafian(Co-founder)in
Co-investorsRA CapitalSamsara BioCapitalSV Health InvestorsDementia Discovery FundM VenturesPfizer Venture Investments
Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform.
AI & Machine LearningBiotechDeep Tech
Yves Ribeill(CEO)
Co-investorsBpifranceElaiaPfizer Venture Investments
EvolveImmune develops immunotherapy treatments for cancer patients.
BiotechHealthtechMedical DevicesBranford, US
Stephen Bloch(Co-founder and Chief Executive Officer)inDonmienne Leung(Manager)Ian Taylor(Manager)Jay Fine(President, Research and Development)
BoardDerek Yoon(Manager)inJasmina Marjanovic(Manager)in
Co-investorsSolasta VenturesElm Street VenturesPfizer Venture InvestmentsTakeda Ventures
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.
AI & Machine LearningBiotechDeep TechHealthtech
Jim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)Jacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in
Co-investorsNexTech VenturesThird Rock VenturesNextech InvestPfizer Venture InvestmentsShangBay Capital LLCAgent Capital
Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.
BiotechHealthtechMedical Devices
Simon Westbrook(Founder and CSO)in
Co-investorsAdvent Life SciencesGilde HealthcareIndex VenturesMedicxiPfizer Venture InvestmentsRedwood Ventures
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesVIBPfizer Venture InvestmentsPolaris Partners
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesVIBPfizer Venture Investments
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCSamsara BioCapitalCanaan PartnersConnecticut InnovationsOUP (Osage University Partners)+6 more
Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.
BiotechDigital HealthMedical DevicesWaltham, US
Jim Broderick(Co-Founder)inJohn Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)Li Peng(Chief Scientific Officer)
Co-investorsMatrix Capital ManagementPfizer Venture InvestmentsSR One Capital ManagementBioHealth Innovation, Inc.Takeda VenturesVertex Ventures HC
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & Chief Executive Officer)in
Co-investorsAscenta CapitalAtlas VentureLightspeed Venture PartnersRA CapitalBessemer Venture PartnersFinchley Healthcare Ventures+3 more
TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.
BiotechDeep TechLongevityMedical DevicesCambridge, GB
Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)
Co-investorsCambridge Innovation CapitalSV Health InvestorsM VenturesPfizer Venture InvestmentsStart CodonDiamond Edge Ventures
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Co-investorsAtlas VentureMission BiocapitalPfizer Venture InvestmentsPivotal Life Sciences
BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).
BiotechHealthtechMedical DevicesSan Diego, US
Jay M. Short(Executive Officer, Director)Richard A. Waldron(Executive Officer)inCarolyn Short(Director)
Co-investorsKeshif VenturesPappas CapitalPfizer Venture InvestmentsHBM Healthcare InvestmentsPappas CapitalSoleus Capital
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)inJeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Founder)in
Co-investors8VCAndreessen HorowitzArtis VenturesCatalio Capital Management, LPFinchley Healthcare VenturesGlobal BioAccess Fund+9 more
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsLifelinkMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPolaris Partners+1 more
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)inJohn McCabe(Chief Financial and Operating Officer)in
Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersLongwood FundPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.+1 more
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalInvus+2 more
Flare is a Shopify app that lets merchants set delivery-date rules by postcode, product, and shipping method so customers only see fulfillable dates at checkout, with automation for cut-off times, order tagging, and 3PL syncing.
E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB
Daniel Parekh-Hill(CEO)inAlex Hooper(CTO)in
Co-investorsEntrepreneur FirstAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalInvus+3 more
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in
Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalEarlybird Venture Capital
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Daniel Olive(Founder)
Co-investorsAgent CapitalAndera PartnersKurma PartnersPfizer Venture InvestmentsPureos BioventuresAlexandria+4 more
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsBackbone VenturesBioMedPartnersGimvLightspeed Venture PartnersMission BiocapitalPfizer Venture Investments+1 more
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundOUP (Osage University Partners)Pfizer Venture InvestmentsQuan Capital+4 more
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Joel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)Annie C. Chen(Director)
Co-investorsAvalon BioVenturesBain Capital Life SciencesPfizer Venture InvestmentsRA CapitalPolaris PartnersVersant Ventures
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsAgent CapitalGimvLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.+5 more
MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.
BiotechHealthtechKingston, US
Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)inIsaac Stoner(CEO)in
BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)in
Co-investorsDolby Family VenturesPfizer Venture InvestmentsSlater Technology FundARCH Venture Partners
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova Partners+6 more
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsM VenturesOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalJJDC
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.
BiotechHealthtechMedical Devices
Co-investorsCambridge Innovation CapitalFast Track InitiativeM VenturesPfizer Venture InvestmentsSeroba Life SciencesTaiho Ventures, LLC+3 more
Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.
AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US
Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)
BoardChristopher O'Donnell(Director)inDavid Rubin(Director)inJames Pavlik(Director)in
Co-investorsArboretum VenturesBaird CapitalMerck Global Health Innovation FundMSD Global Health Innovation FundPfizer Venture InvestmentsWellington Management+1 more
Vibrant Therapeutics develops multispecific antibody-based prodrugs with conditional activation and targeted delivery for patients with oncological, autoimmune, and neurological diseases.
AI & Machine LearningBiotechHealthtech
Co-investorsPfizer Venture Investments
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.